Citadel Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,581
| Closed | -$6.7K | – | 13548 |
|
|
2025
Q1 | $6.7K | Buy |
+15,581
| New | +$152K | ﹤0.01% | 13734 |
|
|
2024
Q4 | – | Sell |
-586
| Closed | -$19.6K | – | 14869 |
|
|
2024
Q3 | $19.6K | Buy |
+586
| New | +$23.2K | ﹤0.01% | 12788 |
|
|
2023
Q2 | – | Sell |
-2
| Closed | -$1.28K | – | 14707 |
|
|
2023
Q1 | $1.28K | Sell |
2
-2
| -50% | -$1.48K | ﹤0.01% | 14332 |
|
|
2022
Q4 | $1.29K | Sell |
4
-18
| -82% | -$7.61K | ﹤0.01% | 14492 |
|
|
2022
Q3 | $11K | Buy |
+22
| New | +$13.4K | ﹤0.01% | 12252 |
|
|
2022
Q2 | – | Sell |
-12
| Closed | -$9.99K | – | 13357 |
|
|
2022
Q1 | $16K | Sell |
12
-24
| -67% | -$26.5K | ﹤0.01% | 13297 |
|
|
2021
Q4 | $41K | Buy |
36
+10
| +38% | +$13.7K | ﹤0.01% | 13356 |
|
|
2021
Q3 | $40K | Sell |
26
-32
| -55% | -$51.2K | ﹤0.01% | 13469 |
|
|
2021
Q2 | $114K | Buy |
58
+31
| +115% | +$56.7K | ﹤0.01% | 12793 |
|
|
2021
Q1 | $50K | Buy |
27
+16
| +145% | +$35.1K | ﹤0.01% | 12901 |
|
|
2020
Q4 | $24K | Sell |
11
-9
| -45% | -$23.3K | ﹤0.01% | 10750 |
|
|
2020
Q3 | $63K | Buy |
+20
| New | +$71.8K | ﹤0.01% | 9513 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | -$27K | – | 9525 |
|
|
2018
Q4 | $27K | Buy |
+1
| New | +$34.3K | ﹤0.01% | 8654 |
|
|
2018
Q2 | – | Hold |
0
| – | -$31K | – | 9008 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 8043 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7618 |
|
|
2017
Q2 | – | Hold |
0
| – | -$46K | – | 7703 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7058 |
|
Other funds holding HEPA
Citadel Advisors's HEPA Position: Q2 2025 in Review
Citadel Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 15,581 shares — an estimated $6.7K sold.
Citadel Advisors first reported a position in HEPA in Q4 2018 and held it in 13 quarters. The position peaked at $114K in Q2 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.
- Citadel Advisors reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 15,581 Hepion Pharmaceuticals shares in Q2 2025, an estimated $6.7K.
- Citadel Advisors first reported a position in Hepion Pharmaceuticals in Q4 2018 and held it in 13 quarters.
- Citadel Advisors's Hepion Pharmaceuticals position peaked at $114K in Q2 2021.
- 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.